Tech Company Financing Transactions
Stalicla Funding Round
Stalicla closed a $2.5 million funding round on 6/30/2025. Backers included Addex Therapeutics and private investors.
Transaction Overview
Company Name
Announced On
6/30/2025
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Undisclosed
Investors
Addex Therapeutics (Lead Investor)
Proceeds Purpose
The company intends to use the funds to sustain operations and program development in neurodevelopmental disorders to prepare its upcoming Series C and the partnering of key programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Avenue de Secheron 15 Campus Biotech Innovation Park
Genève, 1202
Switzerland
Genève, 1202
Switzerland
Phone
Website
Email Address
Overview
STALICLA is a clinical-stage biopharmaceutical company with a team of domain experts, drug developers, clinicians, data scientists and computational biologists working to create NDD precision medicine solutions. 24 employees coming from world leading academic and large pharmaceutical centers (UCLA Geschwind Lab, BCN Super Computing Center, Max Planck Institute, ...) and large Pharmaceutical (Novartis, Roche, Takeda, Lundbeck, ...).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lynn Durham
Chief Financial Officer
Laurent Forestier
Chief Medical Officer
Atul Mahableshwarkar
Chief Operating Officer
Eric Painbeni
Chief Technical Officer
Emre Guney
VP - Client Services
Jean-Marc Hyvelin
Browse more venture capital transactions:
Prev: 6/30/2025: Pimentae venture capital transaction
Next: 6/30/2025: Pixelgen Technologies venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs